Company intelligence / Profile preview
RadioMedix
Houston, Texas, United Statesradiomedix.com ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- Phase 2
01
Overview
The company's lead product AlphaMedix has completed patient enrollment in Phase II trials with promising results. The objective response rate (ORR) endpoint has already been achieved and is more than twice as high as the current standard of care. Top-line data expected in mid-2024. Another product, DetectNET, had a New Drug Application submitted to FDA in January 2020.[3][4]
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalsTargeted Alpha-emitter Therapy (TAT)PET imaging agents
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
Request access →03
Partnerships
Orano MedCurium PharmaVect-HorusOranomed corporation
Beyond the preview
Go deeper on RadioMedix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RadioMedix.